ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

ClinicalTrials.gov ID: NCT02994927

Public ClinicalTrials.gov record NCT02994927. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine

Study identification

NCT ID
NCT02994927
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
331 participants

Conditions and interventions

Interventions

  • Avacopan Drug
  • Azathioprine Drug
  • Cyclophosphamide Drug
  • Prednisone Drug
  • Rituximab Biological

Drug · Biological

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 14, 2017
Primary completion
Sep 6, 2019
Completion
Oct 31, 2019
Last update posted
Mar 23, 2025

2017 – 2019

United States locations

U.S. sites
41
U.S. states
27
U.S. cities
38
Facility City State ZIP Site status
Clinical Trial Site Huntsville Alabama 35801
Clinical Trial Site Phoenix Arizona 85012
Clinical Trial Site Phoenix Arizona 85032
Clinical Trial Site Los Angeles California 90048
Clinical Trial Site Santa Monica California 90404
Clinical Trial Site Aurora Colorado 80045
Clinical Trial Site Washington D.C. District of Columbia 20007
Clinical Trial Site Daytona Beach Florida 32117
Clinical Trial Site Tampa Florida 33612
Clinical Trial Site Atlanta Georgia 30322
Clinical Trial Site Meridian Idaho 83605
Clinical Trial Site Chicago Illinois 60637
Clinical Trial Site Indianapolis Indiana 46202
Clinical Trial Site Kansas City Kansas 66160
Clinical Trial Site Lexington Kentucky 40536
Clinical Trial Site Shreveport Louisiana 71101
Clinical Trial Site Baltimore Maryland 21224
Clinical Trial Site Boston Massachusetts 02114
Clinical Trial Site Boston Massachusetts 02118
Clinical Trial Site Ann Arbor Michigan 48109
Clinical Trial Site Minneapolis Minnesota 55414
Clinical Trial Site Rochester Minnesota 55905
Clinical Trial Site St Louis Missouri 63110
Clinical Trial Site Great Neck New York 11021
Clinical Trial Site Mineola New York 11501
Clinical Trial Site New York New York 10021
Clinical Trial Site New York New York 10032
Clinical Trial Site Chapel Hill North Carolina 27599
Clinical Trial Site Greenville North Carolina 27834
Clinical Trial Site Winston-Salem North Carolina 27103
Clinical Trial Site Cleveland Ohio 44195
Clinical Trial Site Columbus Ohio 43210
Clinical Trial Site Duncansville Pennsylvania 16635
Clinical Trial Site Philadelphia Pennsylvania 19104
Clinical Trial Site Pittsburgh Pennsylvania 15225
Clinical Trial Site Providence Rhode Island 02903
Clinical Trial Site Charleston South Carolina 29406
Clinical Trial Site Dallas Texas 75235
Clinical Trial Site Houston Texas 77030
Clinical Trial Site Salt Lake City Utah 84132
Clinical Trial Site Seattle Washington 98101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 157 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02994927, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 23, 2025 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02994927 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →